In the last years, the application of "nanotechnology “to the field of “medicine” surely represented the most innovative strategy to cope with diseases and it coule be named as nanomedicine applied to difficult-to-treat diseases. As known, in this field of research, the most important goal to be reached is an increase in selectivity and specificity of drug action. Several results with stimulating findings in preclinical or clinical phases have been reached by using nanocarriers, delivering agents to targeted pathologies, and among them, it is known that neuro-pathologies represent a stimulating issue. In fact, the pharmaceutical treatment of Central Nervous System (CNS) disorders is the second largest area of therapy, following cardiovascular diseases. Nowadays, non-invasive drug delivery systems for CNS are actively studied. The nano-technological approach consist of the use of nanosystems (colloidal carriers) which could be polymer-based (nanoparticles, Np) or solid lipid material made (solid lipid nanoparticles, SLNp) and lipid-based (liposomes, LP). In fact, the development of these new delivery systems started with the discovery that properly surface-engineered colloidal vectors, with a diameter around 200 nm, were shown to be able to cross the BBB without apparent damage, and to deliver drugs or genetic materials into the brain. During this talk, an overview will be presented considering the most recent literature results of nanomedicine applied to brain diseases, carried out with all the most popular kinds of nanoparticulate systems, focusing in particular on peptide-decorated nanosystems able to target the CNS.

Nanotechnology for the CNS drug delivery and targeting / Tosi, Giovanni; Ruozi, Barbara; Bondioli, Lucia; Badiali, Luca; Vandelli, Maria Angela; Forni, Flavio. - STAMPA. - 1:(2010), pp. 6-6. ((Intervento presentato al convegno World Congress of Neurotechnology tenutosi a Rome nel 12-14 October 2010.

Nanotechnology for the CNS drug delivery and targeting

TOSI, Giovanni;RUOZI, Barbara;BONDIOLI, Lucia;BADIALI, Luca;VANDELLI, Maria Angela;FORNI, Flavio
2010

Abstract

In the last years, the application of "nanotechnology “to the field of “medicine” surely represented the most innovative strategy to cope with diseases and it coule be named as nanomedicine applied to difficult-to-treat diseases. As known, in this field of research, the most important goal to be reached is an increase in selectivity and specificity of drug action. Several results with stimulating findings in preclinical or clinical phases have been reached by using nanocarriers, delivering agents to targeted pathologies, and among them, it is known that neuro-pathologies represent a stimulating issue. In fact, the pharmaceutical treatment of Central Nervous System (CNS) disorders is the second largest area of therapy, following cardiovascular diseases. Nowadays, non-invasive drug delivery systems for CNS are actively studied. The nano-technological approach consist of the use of nanosystems (colloidal carriers) which could be polymer-based (nanoparticles, Np) or solid lipid material made (solid lipid nanoparticles, SLNp) and lipid-based (liposomes, LP). In fact, the development of these new delivery systems started with the discovery that properly surface-engineered colloidal vectors, with a diameter around 200 nm, were shown to be able to cross the BBB without apparent damage, and to deliver drugs or genetic materials into the brain. During this talk, an overview will be presented considering the most recent literature results of nanomedicine applied to brain diseases, carried out with all the most popular kinds of nanoparticulate systems, focusing in particular on peptide-decorated nanosystems able to target the CNS.
World Congress of Neurotechnology
Rome
12-14 October 2010
1
6
6
Tosi, Giovanni; Ruozi, Barbara; Bondioli, Lucia; Badiali, Luca; Vandelli, Maria Angela; Forni, Flavio
Nanotechnology for the CNS drug delivery and targeting / Tosi, Giovanni; Ruozi, Barbara; Bondioli, Lucia; Badiali, Luca; Vandelli, Maria Angela; Forni, Flavio. - STAMPA. - 1:(2010), pp. 6-6. ((Intervento presentato al convegno World Congress of Neurotechnology tenutosi a Rome nel 12-14 October 2010.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/645474
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact